A comprehensive review of international research has concluded that nicotine-based e-cigarettes are likely to cause cancer of the lungs and mouth, marking what researchers describe as the most definitive assessment yet of vaping's direct cancer risk.
Published in Carcinogenesis, the study was led by UNSW Sydney and drew together experts from multiple institutions including The University of Queensland, Flinders University, The University of Sydney, and several major hospitals. The interdisciplinary team examined evidence from clinical research, animal studies, and laboratory investigations to determine whether vaping itself, independent of traditional smoking, increases cancer risk.
"To our knowledge, this review is the most definitive determination that those who vape are at increased risk of cancer compared to those who don't," said Prof. Bernard Stewart, one of the lead researchers.
The analysis identified multiple carcinogenic substances in e-cigarette aerosols, including volatile organic compounds and metals released when heating coils. Researchers found DNA damage markers in vaping users, evidence of oxidative stress and tissue inflammation, lung tumors in mouse studies, and cellular damage linked to cancer development. The findings proved remarkably consistent across all research disciplines examined.
While the evidence points clearly toward cancer risk, researchers cautioned that determining the precise number of cases attributable to vaping will require longer-term human studies spanning decades. The current assessment remains qualitative rather than providing a numerical estimate of how many people might develop cancer from vaping.
A Gateway to Dual Harm
E-cigarettes entered the Australian market around 2008, marketed as a safer alternative to conventional cigarettes and as a smoking cessation tool. Brightly colored and flavored products gained rapid popularity, particularly among younger users. The Australian Government tightened regulations in 2023, prohibiting disposable and non-therapeutic vapes while restricting therapeutic products to pharmacy sales for smoking cessation only.
Yet a troubling pattern has emerged. Many smokers who switch to vaping end up using both cigarettes and e-cigarettes simultaneously. Recent epidemiological evidence from the United States shows that dual users face a four-fold increased risk of developing lung cancer compared to smokers alone.
"Most of those who use e-cigarettes to quit smoking end up in dual-use-limbo, unable to shake off either habit," said A/Prof. Freddy Sitas, a co-author on the review.
The researchers also note that e-cigarettes are known to serve as a gateway to smoking itself, compounding the cancer risk picture.
The review draws a sobering parallel to the history of tobacco research. It took nearly a century from initial observations in the mid-1800s to the landmark 1964 U.S. Surgeon General's report that officially recognized smoking as a cause of lung cancer. During much of that period, warning signs were dismissed or ignored.
"E-cigarettes were introduced about 20 years ago," Sitas warned. "We should not wait another 80 years to decide what to do."
Author Jessica Williams: "This study fills a critical gap in vaping research, and the consistency of the evidence should force policymakers to act faster than they did with cigarettes."
Comments